An investigation on behalf of investors of Cornerstone Therapeutics, Inc. (NASDAQ:CRTX) in connection with the proposed takeover was announced and NASDAQ:CRTX stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 02/25/2013 --An investigation on behalf of investors in H Cornerstone Therapeutics, Inc. (NASDAQ:CRTX) shares was announced concerning whether the offer by its majority shareholder Chiesi Farmaceutici SpA to acquire Cornerstone Therapeutics, Inc. for a cash purchase price between $6.40 and $6.70 per NASDAQ:CRTX share and the takeover process are unfair to investors in Cornerstone Therapeutics shares.

Investors who purchased shares of Cornerstone Therapeutics, Inc. (NASDAQ:CRTX) prior to February 20, 2013, and currently hold any of those NASDAQ:CRTX shares have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain officers and directors of Cornerstone Therapeutics, Inc. breach their fiduciary duties owed to NASDAQ:CRTX investors in connection with the proposed acquisition.

On Feb 20, 2013, Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced that its Board of Directors has received a letter from its majority Stockholder Chiesi Farmaceutici SpA In that letter Chiesi Farmaceutici SpA, which owns approximately 60% of the outstanding shares of the Cornerstone Therapeutics Inc. (NASDAQ: CRTX) common stock, made a proposal, subject to certain conditions, to acquire the shares of Cornerstone Therapeutics Inc. (NASDAQ: CRTX) common stock that it does not already own for a cash purchase price of between $6.40 and $6.70 per share.

However, given that at least one analyst has set the target price for NASDAQ:CRTX shares at $14.00 and that following the takeover news NASDAQ:CRTX shares jumped in the open market as high as $6.84 per share on Feb. 20, 2013, the investigation a law firm concerns whether the proposed transaction is unfair to NASDAQ:CRTX stockholders.

Given the analyst estimate, its recent share price and that NASDAQ:CRTX shares traded as recently as July 2012 as high as $7.70 per share, the investigation focuses on whether the Cornerstone Therapeutics Board of Directors undertake an adequate sales process, adequately shop the company before entering into the transaction, maximize shareholder value by negotiating the best price, and act in the shareholders' best interests in connection with the proposed sale.

Those who are current investors in Cornerstone Therapeutics, Inc. (NASDAQ:CRTX), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Joelle Day
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com